[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @AcumenPharm Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals, Inc. posts on X about $4552t the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours. ### Engagements: X [#](/creator/twitter::1440022980487225348/interactions)  - X Months XX -XX% - X Year XX -XX% ### Mentions: X [#](/creator/twitter::1440022980487225348/posts_active)  ### Followers: XXX [#](/creator/twitter::1440022980487225348/followers)  - X Months XXX +8.30% - X Year XXX +18% ### CreatorRank: undefined [#](/creator/twitter::1440022980487225348/influencer_rank)  ### Social Influence [#](/creator/twitter::1440022980487225348/influence) --- **Social topic influence** [$4552t](/topic/$4552t) ### Top Social Posts [#](/creator/twitter::1440022980487225348/posts) --- Top posts by engagements in the last XX hours "Exciting news from Acumen: Weve entered a strategic collaboration option and license agreement with JCR Pharmaceuticals to develop a novel Alzheimers therapy using their proprietary J-Brain Cargo platform. Learn more in our joint press release:"  [@AcumenPharm](/creator/x/AcumenPharm) on [X](/post/tweet/1945843933474357630) 2025-07-17 13:52:00 UTC XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Acumen Pharmaceuticals, Inc. posts on X about $4552t the most. They currently have XXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Social topic influence $4552t
Top posts by engagements in the last XX hours
"Exciting news from Acumen: Weve entered a strategic collaboration option and license agreement with JCR Pharmaceuticals to develop a novel Alzheimers therapy using their proprietary J-Brain Cargo platform. Learn more in our joint press release:" @AcumenPharm on X 2025-07-17 13:52:00 UTC XXX followers, XX engagements
/creator/x::AcumenPharm